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Abstract
Background: Temporomandibular disorders (TMDs) are characterized by persistent orofacial pain and have diverse
etiologic factors that are not well understood. It is thought that central sensitization leads to neuronal
hyperexcitability and contributes to hyperalgesia and spontaneous pain. Nonsteroidal anti-inflammatory drugs
(NSAIDs) are currently the first choice of drug to relieve TMD pain. NSAIDS were shown to exhibit anticonvulsant
properties and suppress cortical neuron activities by enhancing neuronal voltage-gated potassium KCNQ/Kv7
channels (M-current), suggesting that specific activation of M-current might be beneficial for TMD pain.
Results: In this study, we selected a new anticonvulsant drug retigabine that specifically activates M-current, and
investigated the effect of retigabine on inflammation of the temporomandibular joint (TMJ) induced by complete
Freund’s adjuvant (CFA) in rats. The results show that the head withdrawal threshold for escape from mechanical
stimulation applied to facial skin over the TMJ in inflamed rats was significantly lower than that in control rats.
Administration of centrally acting M-channel opener retigabine (2.5 and 7.5 mg/kg) can dose-dependently raise the
head withdrawal threshold of mechanical allodynia, and this analgesic effect can be reversed by the specific KCNQ
channel blocker XE991 (3 mg/kg). Food intake is known to be negatively associated with TMJ inflammation. Food
intake was increased significantly by the administration of retigabine (2.5 and 7.5 mg/kg), and this effect was
reversed by XE991 (3 mg/kg). Furthermore, intracerebralventricular injection of retigabine further confirmed the
analgesic effect of central retigabine on inflammatory TMJ.
Conclusions: Our findings indicate that central sensitization is involved in inflammatory TMJ pain and
pharmacological intervention for controlling central hyperexcitability by activation of neuronal KCNQ/M-channels
may have therapeutic potential for TMDs.
Background
Temporomandibular disorders (TMDs) are an assort-
ment of clinical conditions characterized by pain in the
temporomandibular joint (TMJ) and/or the masticatory
muscles [1]. The main symptoms exhibited by TMD
patients include orofacial pain, altered jaw mechanics,
impaired masticatory function and sounds from the
TMJ, with few or no peripheral tissue abnormalities [2].
As TMD pain persists over time, it is thought that
changes in the central nervous system (CNS) lead to
altered neuronal processing in the brain, with central
sensitization and hyperexcitability, ultimately affecting
perception of TMD pain [3,4]. Accumulating clinical
evidence shows that patients with TMDs have general-
ized hypersensitivity of CNS nociceptive pathways,
resulting in amplification of minimal nociceptive stimuli
arising from the peripheral tissues [1,5].
TMDs are often managed clinically by modifying drug
regimens to achieve desired therapeutic end points, but
treatment of TMDs remains a clinical challenge because
its diverse etiologic factors are not well understood
[1,3,4]. Although anticonvulsants which act on
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to prevent epileptic seizures by suppressing neuronal
hyperexcitability [1,6,7], they are often prescribed “off-
label” for treatment of TMDs, suggesting central inter-
vention to suppress hyperexcitability may be an effective
clinical approach. The anticonvulsant gabapentin that
binds to a2δ, an auxiliary subunit of voltage-gated cal-
cium channels, can significantly relieve TMD pain com-
pared to placebo groups [8], providing clinical evidence
that central hyperexcitability is involved in the genera-
tion of TMD pain [5].
The anticonvulsant retigabine which was discovered in
the 1980 s has been shown to attenuate inflammatory
and neuropathic pain in rodent animal models [9-13],
and to decrease neuronal excitability of noceiceptive
neurons and C-type nerve fibers [14,15]. Retigabine is
best described for its novel mechanism of action that
involves specific activation of neuronal M-current
encoded by Kv7.2-7.5 voltage-gated potassium channels
expressed in various neurons of the peripheral and cen-
tral nervous systems [16-19]. The M-current is a sub-
threshold voltage-gated K
+ current that serves as a
brake to suppress abnormal ectopic discharges of neu-
rons and control neuronal hyperexcitability
[14,15,20-22].
Nonsteroidal anti-inflammatory drugs (NSAIDs) that
act as nonselective inhibitors of COXs (cyclooxygenases)
are widely used as first-line drugs for TMD treatment
[7,23], but little is understood about their mechanism of
action for the relief of TMD pain. Two NSAIDs, diclofe-
nac sodium and meclofenamic acid, were shown to exhi-
bit anticonvulsant activities by activation of the KCNQ/
Kv7 channel [24], suggesting that opening KCNQ/Kv7
channels may be beneficial for pain relief of TMDs.
Therefore, we hypothesized that central suppression of
neuronal hyperexcitability by activation of central
KCNQ/Kv7 channel function may lead to reverse the
pain of inflamed TMJs. To evaluate this concept, we
took advantage of the centrally acting retigabine and
investigated its effect on mechanical allodynia in
inflammed temporomandibular joints induced by com-
plete Freund’s adjuvant (CFA) in rats. In this study, we
found that retigabine can dose-dependently elevate the
pain threshold of TMJ inflammation induced by CFA,
and this effect was antagonized by the specific channel
blocker XE991. The characteristic reduction of food
intake secondary to TMJ dysfunction induced by the
inflammation also was reversed by retigabine in a dose-
dependent manner. Our findings for the first time indi-
cate that the anticonvulsant compound retigabine which
activates KCNQ/Kv7 channels may provide a potential
treatment for TMD.
Results
Inflamed TMJ induced by CFA
We started by validating CFA induces TMJ inflamma-
tion in rats. As previously described, the injection of
CFA into the temporomandibular joint (TMJ) induced
significant mechanical hypersensitivity in the TMJ
region associated with inflammation [25-27]. Twenty-
four hours after the CFA injection in the TMJ, chromo-
dacryorrhea in the eyes and intense redness and swelling
over the TMJ region were observed in all CFA-injected
groups, but were not found in the control group. The
injection site was anatomically confirmed by dissection
of the TMJ region. Histopathologic examination showed
the synovial tissues were hypertrophied with an increase
of infiltrating leucocytes in the TMJ following CFA
injection [28,29], while there were no such changes in
the control TMJ without CFA (Figure 1). Angiogenesis
Figure 1 Histopathologic examination of inflammatory TMJ region induced by CFA in rats. A. Photomicrograph of TMJ 24 hours after
injection of saline as a normal control. B. Photomicrograph of TMJ 24 hours after injection of CFA. Exuberant hypertrophy of the synovial tissue,
angiogenesis in the enlarged area (indicated by arrowhead) and fibrin-like exudates (indicated by arrow) in the joint space were observed
(Magnification × 4, scale bar = 200 μm).
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also observed in the CFA injected TMJ as compared to
the control joint (Figure 1), indicating that injection of
CFA into the TMJ successfully induced inflammation.
In behavioral tests, the mechanical head withdrawal
threshold was measured at time points 6, 12, 24, 48 and
96 hours after CFA injection into the TMJ region.
Mechanical hypersensitivity developed and reached the
lowest head withdrawal threshold at 12 hours (Figure 2),
and mechanical hypersensitivity was maintained for at
least 4 days, compared with saline group (Figure 2).
This result confirmed the relationship of inflammation
in the TMJ induced by CFA and mechanical hypersensi-
tivity, and this model was used for the entire study.
Attenuation of mechanical allodynia of inflamed TMJ by
activation of KCNQ/Kv7 with retigabine
To test whether retigabine administration can attenuate
the mechanical allodynia of inflamed TMJ, we first mea-
sured the analgesic effect of morphine on the inflamed
TMJ pain. Morphine (5 mg/kg, i.p.) as a positive control
reversed the decreased head withdrawal threshold of
rats with inflamed TMJ (Figure 3). We then tested the
effect of retigabine on the head withdrawal threshold.
Intraperitoneal administration of retigabine resulted in
dose-dependent attenuation of mechanical TMJ allody-
nia (Figure 3). The effect of retigabine on inhibition of
mechanical hypersensitivity was observed 15 min after
retigabine injection, and lasted for about 90 min (Figure
3).
It is known that the specific KCNQ/Kv7 channel
blocker XE991 can reverse the effect of retigabine on
inflammatory and neuropathic pain [9-11]. To further
confirm the specific action of retigabine on TMJ inflam-
matory pain through activation of KCNQ/Kv7 channel
function, we used the blocker XE991 to test whether the
effect of retigabine could be reversed. Figure 4 shows
that the effect of retigabine (7.5 mg/kg) on head with-
drawal threshold can be antagonized by XE991 (either 3
mg/kg or 1 mg/kg), compared with the vehicle control
in the presence or absence of XE991 (3 mg/kg), indicat-
ing that retigabine reduction of allodynia in the inflamed
TMJ can be reversed by this blocker. As a control, we
also tested both retigabine and XE991 for effect on head
withdrawal threshold in normal rats. The result showed
that neither retigabine nor XE991 have any effect on the
baseline head withdrawal threshold, compared with the
vehicle group (Figure 5A).
Food intake with inflamed TMJs was increased by
activation of KCNQ/Kv7 with retigabine
To further confirm the effect of retigabine, we also mea-
sured food intake. The amount of food intake is nega-
tively associated with TMJ pain due to the limited
movement of the TMJ after inflammation [30,31]. After
injection of CFA into TMJ, rats were kept one per cage
a n ds u p p l i e dw i t hw a t e rf o r1 2h ,b u tw e r en o tg i v e n
food. The rat was then given food but no water, and the
Figure 2 Development of mechanical allodynia in TMJ induced
by CFA in rats. Head withdrawal threshold was measured using an
electric von Frey anesthesiometer over a 96-hour period for the
saline control group (open squares) and the CFA group (filled
triangles). CFA was injected at time 0 and the withdrawal threshold
was measured at time points 6 h, 12 h, 24 h, 48 h, and 96 h. The
lowest head withdrawal threshold occurred 12 h after CFA injection
and was maintained for about 36 h (P < 0.001 for time period of 12
to 96 hours, compared with the saline group, two-way ANOVA).
Figure 3 Attenuation of mechanical TMJ allodynia by
anticonvulsant retigabine in a dose-dependent manner. Drugs
(Mor: morphine and RTG: retigabine) of different concentrations
were administered to rats with TMJ inflammation by intraperitoneal
(i.p) injection at time 0. The withdrawal threshold was measured at
15, 30, 60 and 120 min after drug treatment, with morphine as a
positive control. Statistical significance of p < 0.05 (two-way ANOVA
followed by Bonferroni post hoc) was obtained for the period 15-60
min for the groups CFA + morphine (5 mg/kg), and CFA +
retigabine (7.5 mg/kg or 2.5 mg/kg), as compared with the group
CFA + vehicle.
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recorded as the food intake. Without induction of TMJ
inflammation, normal rats consumed about 4 grams of
food, and the same amount of food was consumed by
the vehicle, retigabine (7.5 mg/kg) and XE991 groups (3
mg/kg), indicating that neither retigabine nor XE991 has
any effect on basal consumption of food in normal rats
(Figure 5B).
In contrast, food intake was significantly decreased in
rats with TMJ inflammation (Figure 6). Administration
of retigabine in doses from 2.5 mg/kg to 7.5 mg/kg
increased the food intake of TMD rats about 1.0 to 3.0-
fold, as compared with the vehicle control group (Figure
6). Increased food intake associated with retigabine was
reversed by XE991 at doses of 1 mg/kg or 3 mg/kg (Fig-
ure 7). These results were consistent with the results of
measurement of elevated head withdrawal threshold,
further confirming attenuation of mechanical allodynia
in inflamed TMJs by retigabine through activation of
the KCNQ/Kv7 channel function.
Analgesic effect with central intracerebroventricular
administration of retigabine
In order to further confirm attenuation of allodynia with
inflamed TMJs was due to reduction of central excitabil-
ity by activation of KCNQ channels, we injected retiga-
bine into the rats with TMJ inflammation
intracerebroventricularly (i.c.v). Retigabine (45 or 15 μg)
as well as the positive control morphine (1 μg) signifi-
cantly elevated the mechanical head withdrawal thresh-
old, as compared with the vehicle control (Figure 8).
Similarly, food intake was also increased with icv injec-
tion of retigabine (15 μg) into rats with TMJ inflamma-
tion, as compared with the vehicle control (Figure 9).
These results indicate that retigabine resulted in reduced
Figure 4 Retigabine reduced allodynia reversed by the blocker
XE991. RTG (retigabine) at 7.5mg/kg attenuated the inflamed TMJ
allodynia, and the effect was reversed by XE991 (3 mg/kg or 1 mg/
kg) in a dose- and time-dependent manner. XE991 alone (3 mg/kg)
had no effect on the head withdrawal threshold in TMJ
inflammation. Statistical significance of p < 0.05 (two-way ANOVA
followed by Bonferroni post-test) was obtained for the period 15-60
min for the group CFA + RTG 7.5 mg/kg, as compared with CFA +
vehicle; and was also obtained for the two groups CFA + RTG 7.5
mg/kg + XE 3 mg/kg, and CFA + RTG 7.5 mg/kg + XE 1 mg/kg, as
compared with the group of CFA + RTG 7.5 mg/kg. XE: XE991, RTG:
retigabine. The plus sign (+) in the legend indicates CFA treatment.
Figure 5 Head withdrawal threshold and food intake in normal rats was not affected by retigabine and XE991. (A), RTG (retigabine) at
7.5 mg/kg and XE991 at 3 mg/kg had no effect on head withdrawal threshold of normal rats without TMJ inflammation, as compared with the
vehicle (two-way ANOVA followed by Bonferroni post-test). (B), Food intake values in normal rats without TMJ inflammation. During the 2 h
period of food intake, retigabine (RTG) and XE991 had no effect on normal food intake in rats without TMJ inflammation. The food intake value
in the baseline group (4.8 g) indicates the normal value obtained before drug or vehicle administration. The food intake values in the groups
treated by retigabine (7.5 mg/kg, i.p.) and XE991 (3 mg/kg, i.p.) were 4.5 g and 4.8 g, respectively. The food intake value of the vehicle group
was 5.5 g. There was no statistical significance between these four groups (one-way ANOVA followed by Dunnett’s test).
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firming the analgesic effect of retigabine on TMJ inflam-
mation through central suppression of neuronal
hyperexcitability.
Discussion
We were intrigued by the recent study in which two
NSAIDs, the class of drugs which are the first line clini-
cal treatment for TMD pain, were shown to suppress
epileptic activities by activation of neuronal voltage-
gated KCNQ/Kv7 channels [24]. This observation led us
to hypothesize that the anticonvulsant retigabine that
specifically opens KCNQ/Kv7 channels might be benefi-
cial for TMD pain. In this study for the first time, we
have shown that central activation of neuronal KCNQ/
Kv7 potassium channels by retigabine can attenuate
allodynia associated with temporomandibular joint
inflammation in rats. Our findings have several implica-
tions: first, they serve as an in vivo validation that neu-
ronal KCNQ/Kv7 potassium channels are a target for
TMJ pain; second, the positive modulation of neuronal
KCNQ/Kv7 potassium channels that suppress excessive
excitability can be therapeutically beneficial to TMDs;
third, the anticonvulsant retigabine which is effective in
clinical trials for reduction in seizures may also prove to
Figure 6 Increased food intake with retigabine administration
in rats with TMJ inflammation injected with CFA. The food
intake in the baseline group was measured in normal rats without
CFA injection. Twenty-four hours after CFA injection, the effect of
retigabine or morphine as a positive control on food intake was
measured, and compared with the vehicle (CFA alone) group.
Retigabine enhanced the food intake in dose-dependent manner, as
compared with the vehicle. Statistical significance was obtained
between the vehicle group and the two groups RTG (7.5 mg/kg, i.p.,
p < 0.01; and 2.5 mg/kg, i.p., p < 0.05, one-way ANOVA followed by
Dunnett’s test), and the morphine group (Mor) (5 mg/kg, i.p., p <
0.05, one-way ANOVA followed by Dunnett’s test).
Figure 7 Enhanced food intake by retigabine was reversed by
the blocker XE991. The food intake in the baseline group
represents the value for normal rats without TMJ inflammation. The
effect of retigabine or retigabine and XE991 was tested 24 hours
after CFA injection. The food intake in the vehicle group indicates
the value for rats with TMJ inflammation induced by CFA.
Retigabine at a dose of 7.5 mg/kg, i.p. significantly increased the
food intake, as compared with the vehicle group (p < 0.005, one-
way ANOVA followed by Dunnett’s test). Co-injection (i.p.) of XE991
(at 3 mg/kg or 1 mg/kg) with RTG reversed the food intake which
had been increased by RTG (7.5 mg/kg, p < 0.05, one-way ANOVA
followed by Dunnett’s test), as compared with the vehicle group.
XE991 at 3 mg/kg had no effect on food intake in rats with TMJ
inflammation (p = 0.98), compared with vehicle group. RTG:
Retigabine; XE: XE991.
Figure 8 Allodynia was attenuated by central administration of
retigabine in rats with TMJ inflammation. Intracerebroventricular
injection of retigabine (45 μgo r1 5μg) as well as morphine (1 μg)
as positive control raised the head withdrawal threshold from 15 to
60 min, compared with the vehicle control (p < 0.05 two way
ANOVA followed by Bonferroni post-test).
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finally, central hyperexcitability is involved in the
mechanism of inflammatory TMJ pain.
TMD pain is considered to be a disorder characterized
by central hyperexcitability and sensitization, and this is
further supported by the fact that central-acting phar-
macological agents including the anticonvulsant gaba-
pentin show clinical efficacy for analgesia and anti-
hyperalgesia in treatment of TMDs [7,8]. Neuronal
hyperexcitability is a common underlying mechanism of
neurological disorders such as epilepsy and chronic pain
including TMDs. These disorders are currently managed
by drugs that are dampen neuronal hyperexcitability
through voltage-gated sodium channel inhibition, modu-
lation of voltage-gated calcium channels and their auxili-
ary subunits, and inhibitory GABAergic
neurotransmission [6]. Although the cause of excessive
neuronal activity varies, an increase in voltage-gated K
+
channel conductance can suppress the hyerexcitability,
thus providing a therapeutic potential for chronic pain.
The voltage-gated potassium channels play a common
role in repolarizing membrane potential of neurons dur-
ing action potential firing. Typical neuronal firing is
characterized by a specific voltage threshold for action
potential, and the opening of potassium channels below
the threshold (or subthreshold) will lead to the inhibi-
tion of initiation and propagation of action potential.
Head withdrawal is a response to nociceptive stimuli
applied to the facial skin, and head withdrawal threshold
is regulated by excitabilityo fT R Gn e u r o n si n n e r v a t i n g
the TMJ [32]. It has been shown that voltage-gated
transient potassium (Kv) current regulates the excitabil-
ity of TRG neurons, and the Kv channel density is lower
in inflamed TMJ, leading to increased excitability of
TRG neurons [25,33]. In terms of action mechanism of
retigabine, there is a lack of literature report as to
whether KCNQ/M-current is expressed in TRG neu-
rons, and our data can not rule out retigabine partially
working on peripheral TRG neurons for activation of Kv
current.
The existence of a low-threshold, depolarization acti-
vated potassium current was described in 1980 and is
referred to as the “M-current” because it was inhibited
by the cholinergic agonist muscacine [34,35]. The M-
current is active in the voltage range for action potential
initiation and is therefore of particular importance in
regulating the dynamics of the neuronal firing of noci-
ceptive neurons and excitability of C-type nerve fibers
[14,15]. The M-current turns on slowly following mem-
brane depolarization and does not inactivate with sus-
tained depolarization. The molecular identity that
underlies the M-current was discovered as a result of
identification of mutations in human potassium channel
subunits referred to as KCNQ2 (Kv7.2) and KCNQ3
(Kv7.3) from idiopathic generalized epilepsy patients
[36,37]. It was demonstrated that the M-current channel
is formed by KCNQ2 and KCNQ3 subunits as hetero-
multimers as well as homomultimers [17]. M-current
can also possibly be generated by heteromultimers with
other KCNQ subunits such as KCNQ5 [38]. The expres-
sion of KCNQ subunits has also been confirmed in the
CNS and DRG sensory neurons [10,39,40], suggesting
the role the channels play in regulating neuronal
excitability.
There are no previously published studies in the litera-
ture evaluating the analgesic effect of retigabine on TMJ
pain. Pharmacological treatment of TMDs remains a
clinical challenge because of diverse etiologic factors
that contribute to the severity of TMDs pain. Without a
clear rationale based on mechanism for selection of
drugs, a wide-spectrum of available drugs such as
NSAIDs, antidepressants, benzodiazepines, muscle relax-
ants, corticosteroids, anticonvulsants and opioids etc,
has been used to achieve desired therapeutic end points
for TMDs. Accumulating clinical evidence shows that
patients with TMDs have generalized central hypersensi-
tivity, suggesting that anticonvulsant drugs may have
therapeutic potential [1,5,8]. Retigabine is a promising
new anticonvulsant that has been shown to have a
broad-spectrum of activity in animal models of epileptic
seizures with a recently described novel mechanism of
action which involves specific activation of KCNQ2-5
(Kv7.2-7.5) channels [9,41-43]. There are preliminary
indications that in the rat the half-life and concentra-
tions of retigabine are higher in the brain than in the
Figure 9 Increased food intake secondary to central
administration of retigabine. Intracerebroventricular administration
of retigabine at a dose of either 45 μgo r1 5μg( p < 0.05), as well
as the positive control morphine group 1 μg( p < 0.05, one-way
ANOVA followed by Dunnett’s test) raised the food intake in rats
with TMJ inflammation.
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hyperalgesia and allodynia in animal models of neuro-
pathic pain [9,10]. In previous studies of rotarod test
that evaluates balancing and coordination for CNS side
effect [12], a dose of 10 mg/kg retigabine was given to
rats intraperitoneally to test its side effects of central
nervous system. The administration of retigabine caused
a short period of impaired motor performance, although
the motor performance of all rats returned to baseline
level 15 min after administration of the drug [12]. In
order to avoid performance impairment, we reduced the
dose to 7.5 mg/kg, and no significant performance
impairment was observed during the behavior test in
our study. We also tested the effect of retigabine and
XE991 on normal rats, and we did not observe any
abnormal pain sensation or abnormality of food intake
with these agents. This result indicates that that retiga-
bine preferentially functions in hyperactive neurons,
which is consistent with the observation that the effect
of retigabine is profound in depolarized neurons and
small in hyperpolarized axons [14,15]. Taken these find-
ings together, the pharmacological effect of retigabine
on TMJ inflammation was specific, and was not due to
any toxic effect [43].
Conclusions
This study shows the analgesic effect of retigabine oper-
ates through specific activation of neuronal KCNQ/Kv7
in TMDs in rats. Because of the central acting property
of retigabine, our results indicate that the central hyper-
sensitivity of TMD patients may be an important
mechanism in this disease. Therefore, the reduction of
central hyperexcitability by anticonvulsant agents may
represent a potential therapeutic alternative for TMDs.
Methods
Animals
Adult male Sprague Dawley rats (190-220 g) were used
in this study. The experimental protocols were approved
by the Animal Use and Care Committee of Peking Uni-
versity and were consistent with the Ethical Guidelines
of the International Association for the Study of Pain.
The rats were housed under controlled temperature (22
± 1°C), on a 12 hr light/dark cycle and had free access
to food and water.
Induction of temporomandibular joint (TMJ) inflammation
by complete Freund’s adjuvant (CFA)
Because TMD pain is significantly related to synovitis,
internal derangement and osteoarthritis, indicating that
joint inflammation could be a major reason for TMD
pain, TMJ inflammation is used universally to mimic
TMD pain [44-47]. After baseline measurements of head
withdrawal threshold and food intake (see below) were
completed, rats were briefly sedated with chloral hydrate
(300 mg/kg) and then 50 μl of CFA suspension (1:1,
CFA fluid/saline suspension) (Sigma, St. Louis, MO,
USA) per side were injected into the bilateral TMJ with
a 30-gauge needle. For the control rats, 50 μlo fs a l i n e
per side were injected into the bilateral TMJs [26,27].
TMJ inflammation was evaluated by physical examina-
tion and histopathology.
Tissue preparations and staining of TMJ
The TMJ was removed and fixed in 4% paraformalde-
hyde in phosphate buffered solution (PBS) and deminer-
alized in 15% EDTA. The specimens were dehydrated in
graded alcohols and xylene, embedded in paraffin, and
cut serially into 5-μm sagittal sections. The sections
were stained with hematoxylin-eosin. After the staining,
the sections were imaged using Olympus BX60 system
microscope (Olympus Corp., Tokyo, Japan) containing
ApogeeKX85 digital camera (Apogee Biotechnology
Corporation, USA) and the images were acquired by
Image Pro Plus software (Media Cybernetics, Inc., USA)
without any subsequent image manipulation.
Measurement of head withdrawal threshold
At least 1 week before the mechanical nociceptive
threshold testing, the rats were housed in the testing
room with 3-4 animals per cage. The head withdrawal
threshold was measured as previously reported [27].
Briefly, 24 h after injection of CFA into the TMJ, the
rats were habituated to lean against the experimenter’s
gloved hand (regular leather working glove) standing on
their hind paws. During the test session, the rats were
unrestrained but remained motionless. A filament con-
veying progressive, increasing forces from an electronic
von Frey Anesthesiometer (IITC Life Science, CA, USA)
was applied to the bilateral TMJ regions until the head
was withdrawn and the applied force was recorded. The
combined head withdrawal threshold measured from
both sides of TMJ regions was calculated as mean ±
standard error of mean (s.e.m.) based on at least five
measurements per joint with 6-8 rats per group.
Food intake
Food intake is negatively associated with TMJ inflamma-
tion/pain and can be used as an indicator of TMJ
inflammation/pain [26,30,31]. We measured food intake
as previously described with minor modifications,
whereby rats were initially fasted over a period of time
and then the amount of food subsequently eaten was
measured over a limited interval. Briefly, after injection
of CFA into the TMJ, each rat was kept in one cage
supplied with water but without food for 12 h. The rat
was then fed with food but without water and the
amount of food eaten by the rat during 2 h was
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substantial quantity of food was put into each cage, and
the initial amount of food was the same in every cage.
This food was carefully kept dry during the test session
to avoid artefactual weight alteration, and the residual
food was weighted. The difference between the initial
and residual amount of food was recorded as the
amount of food intake during 2 hours.
Drugs administration
Before behavioral testing, the anticonvulsant retigabine
or the KCNQ/Kv7 channel blocker XE991 (Tocris, UK)
was dissolved in tween 80 (Sigma, St. Louis, MO, USA)
and saline. The vehicle used in this study was a mixture
of tween80 (Sigma, St. Louis, MO, USA) and saline
(0.9% NaCl, autoclaved before use) in a ratio of 1:9 (v/
v). Drugs were diluted to desired concentrations one
d a yb e f o r et h ee x p e r i m e n t sa n dw e r es t o r e da t- 2 0 ° C .
All drug solutions were administered to rats intraperito-
n e a l l ya tav o l u m eo f1 0m lp er kilogram body weight.
Intraperitoneal (i.p.) injection of drug solutions and
behavior testing were conducted on the basis of a dou-
ble-blind and randomized design, in which one experi-
menter took the charge of drug injection and
randomized rats dividing, whereas another experimenter
who was blind to drug administration and grouping,
conducted the measurements of head withdrawal
threshold and food intake.
Intracerebroventricular catheterization and injection
Surgery was carried out as previously described [48].
Briefly, the anesthetized rat was placed in a stereotaxic
frame. A skin incision was made on the skull and the
bregma was located. An i.c.v. guide cannula (21-gauge)
was inserted stereotaxically (coordinates: 0.6 mm caudal
to bregma, 1.6 mm lateral to the midline, 1.8 mm
beneath the surface of the skull). Two screws were
attached to the skull with dental cement (Harward Den-
tal GmbH, Berlin, Germany), securing the catheter to
the skull. After the experiment the position of the cathe-
ter was examined. The rat was sacrificed by intraperito-
neal chloral hydrate. Immediately after death, dye (30 ul
1% methylene blue) was injected intracerebroventricu-
larly. To confirm the accuracy of catheterization and
injection, the coronal sections (30 μm) of the brain were
sliced on a cryostat and the perforative lesion with blue
dye were observed in the cavity and wall of cerebroven-
tricle under the examination of microscopy. Retigabine
and morphine were dissolved in Dimethyl sulfoxide
(DMSO)(Sigma, St. Louis, MO, USA) in desired concen-
tration 1 day before the experiment. The drugs were
given in a volume of 2 ul and the pure DMSO as con-
trol was administered in vehicle group. The behavior
experiments were conducted on the basis of a double-
blind and randomized design as described in above sec-
tion of drug administration.
Data analysis
Statistical analysis was performed with GraphPad Prism
(the 5th edition, GraphPad Software, USA) for Win-
dows. All data were presented as mean ± s.e.m. Statisti-
cal significance between multiple groups was examined
by one or two-way ANOVA with appropriate post hoc
test (see figure legends for details). A value of p <0 . 0 5
was considered to be statistically significant.
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